Background: Although heavy-metal burdens have been estimated using global burden of disease (GBD) and environmental burden of disease (EBD) frameworks, Korea-specific assessments combining measured blood concentrations with local exposure–response evidence remain limited. We quantified the disease burden attributable to blood lead and cadmium among Korean adults.Methods: Blood lead and cadmium data from KoNEHS Cycle 5 (2021–2023) were survey-weighted to represent Korean adults and analyzed using outcome-specific age and sex restrictions (≥20 or ≥30 years; women ≥50 years). A systematic review identified eligible Korean adult epidemiological studies published during 2016–2025. Exposure–response functions were integrated with national mortality, morbidity, population, life expectancy, and disability-weight data. Lead outcomes included non-accidental and cancer mortality, hypertension, coronary artery stenosis, and hearing loss; cadmium outcomes included hypertension, hearing loss, and osteoporosis. Burdens were expressed as population attributable fractions (PAFs), years of life lost (YLLs), and years lived with disability (YLDs).Results: Lead-attributable PAFs were 15.7%–34.5% for non-accidental mortality and 28.2%–50.8% for cancer mortality, corresponding to 4,605–13,979 and 868–1,823 YLLs, respectively. Hypertension produced the largest morbidity burden for both metals: lead-attributable PAFs of 4.2%–11.8% generated 127,460–396,435 YLDs, while cadmium-attributable PAFs of 7.2%–16.9% generated 224,887–594,924 YLDs. Cadmium-attributable osteoporosis among women aged ≥50 years yielded PAFs of 10.2%–26.6% and 33,573–104,240 YLDs. The 95% confidence intervals excluded the null for all selected outcomes except hearing loss, for which estimates were imprecise.Conclusions: The substantial estimated burdens, particularly for hypertension, support population-wide exposure reduction and continued biomonitoring of lead and cadmium.